We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice.
- Authors
Tirrò, Elena; Martorana, Federica; Romano, Chiara; Vitale, Silvia Rita; Motta, Gianmarco; Di Gregorio, Sandra; Massimino, Michele; Pennisi, Maria Stella; Stella, Stefania; Puma, Adriana; Gianì, Fiorenza; Russo, Marco; Manzella, Livia; Vigneri, Paolo
- Abstract
Thyroid cancer comprises different clinical and histological entities. Whereas differentiated (DTCs) malignancies are sensitive to radioiodine therapy, anaplastic (ATCs) and medullary (MTCs) tumors do not uptake radioactive iodine and display aggressive features associated with a poor prognosis. Moreover, in a majority of DTCs, disease evolution leads to the progressive loss of iodine sensitivity. Hence, iodine-refractory DTCs, along with ATCs and MTCs, require alternative treatments reflective of their different tumor biology. In the last decade, the molecular mechanisms promoting thyroid cancer development and progression have been extensively studied. This has led to a better understanding of the genomic landscape, displayed by thyroid malignancies, and to the identification of novel therapeutic targets. Indeed, several pharmacological compounds have been developed for iodine-refractory tumors, with four multi-target tyrosine kinase inhibitors already available for DTCs (sorafenib and lenvatinib) and MTCs (cabozantib and vandetanib), and a plethora of drugs currently being evaluated in clinical trials. In this review, we will describe the genomic alterations and biological processes intertwined with thyroid cancer development, also providing a thorough overview of targeted drugs already tested or under investigation for these tumors. Furthermore, given the existing preclinical evidence, we will briefly discuss the potential role of immunotherapy as an additional therapeutic strategy for the treatment of thyroid cancer.
- Subjects
IODINE isotopes; THYROID cancer; ANAPLASTIC thyroid cancer; PROTEIN-tyrosine kinases; KINASE inhibitors
- Publication
Genes, 2019, Vol 10, Issue 9, p709
- ISSN
2073-4425
- Publication type
Article
- DOI
10.3390/genes10090709